FIELD: biotechnology.
SUBSTANCE: invention relates to new conjugates of inhibitory nucleic acids. The invention discloses a chemical compound capable of inhibiting the expression of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene.
EFFECT: siRNA conjugate according to the invention can be used in medicine to effectively reduce cholesterol in the blood plasma, including in the treatment of hypercholesterolemia.
24 cl, 6 ex, 8 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD OF PRODUCTION AND USE | 2020 |
|
RU2816898C2 |
| CONJUGATES AND THEIR OBTAINING AND APPLICATION | 2018 |
|
RU2795400C2 |
| NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN CELL | 2018 |
|
RU2822093C1 |
| NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING IT, AS WELL AS METHOD FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2782211C2 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
| SILENSING OF TGF-BETA 1 AND Cox-2 USING siRNA DELIVERED IN A POLYPEPTIDE NANOPARTICLE, SINGLE AND IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF MALIGNANT NEOPLASM | 2019 |
|
RU2797510C2 |
| AGENTS FOR RNAi, COMPOSITIONS AND METHODS OF THEIR USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TRANSTHYRETIN (TTR) | 2012 |
|
RU2804776C2 |
| NUCLEIC ACID MOLECULES FOR REDUCING THE LEVEL OF PAPD5 OR PAPD7 MRNA FOR TREATING INFECTIOUS HEPATITIS B | 2017 |
|
RU2768699C2 |
| PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS OF TREATING TUMORS | 2019 |
|
RU2810906C2 |
